脂肪性肝炎肝细胞癌（SH-HCC）目前被认为是 HCC 的一种独特的组织学亚型。预后以及确定定义 SH-HCC 所需的脂肪性肝炎数量的具体标准仍不清楚。从 505 例 HCC 病例（2010-2019 年）中排除所有公认的 HCC 亚型后，剩余病例被归类为传统 HCC（CV-HCC） （n = 223）。 SH-HCC 病例 (n = 171) 根据脂肪性肝炎的百分比进一步分为以下几组：5% 或以上、30% 或以上和 50% 或以上。丙型肝炎病毒感染是主要的基础肝病在 CV-HCC 和 SH-HCC 组中。与 CV-HCC 病例相比，代谢功能障碍相关的脂肪性肝病（以前称为非酒精性脂肪肝病）在具有不同脂肪肝截止值的所有 SH-HCC 病例中更为普遍。 CV-HCC 组和 SH-HCC 组之间背景肝脏纤维化阶段没有差异。具有不同截止值的 SH-HCC 表现出肿瘤细胞中糖原核、Mallory-Denk 小体和透明球的存在显着增加。生存分析并未揭示 CV-HCC 和 SH-HCC 组以及具有不同脂肪性肝炎临界值的 SH-HCC 患者之间的总生存率存在显着差异。SH-HCC 患者的瘤内脂肪性肝炎程度似乎并不显着。预后因素。肿瘤中存在的脂肪性肝炎被认为是 HCC 的组织病理学模式之一。© 作者 2024。由牛津大学出版社代表美国临床病理学会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需更多信息，请联系journals.permissions@oup.com。

Steatohepatitic hepatocellular carcinoma (SH-HCC) is currently recognized as a distinct histologic subtype of HCC. The prognosis and specific criteria for determining the amount of steatohepatitis required to define SH-HCC are still unclear.After excluding all recognized HCC subtypes from 505 HCC cases (2010-2019), the remaining cases were categorized as conventional HCC (CV-HCC) (n = 223). The cases classified as SH-HCC (n = 171) were further divided into groups based on the percentage of steatohepatitis: 5% or more, 30% or more, and 50% or more.Hepatitis C virus infection was the predominant underlying liver disease in both the CV-HCC and SH-HCC groups. Metabolic dysfunction-associated steatotic liver disease (formerly nonalcoholic fatty liver disease) was more prevalent in all cases of SH-HCC with different steatohepatitic cutoffs than in cases of CV-HCC. There were no differences in the stage of fibrosis of the background liver between the CV-HCC and SH-HCC groups. SH-HCC with different cutoffs exhibited a notable increase in the presence of glycogenated nuclei, Mallory-Denk bodies, and hyaline globules in tumor cells. Survival analysis did not reveal substantial differences in overall survival between the CV-HCC and SH-HCC groups and among patients with SH-HCC with different steatohepatitis cutoffs.The degree of intratumoral steatohepatitis in patients with SH-HCC does not appear to be a notable prognostic factor. The presence of steatohepatitis in the tumor is better recognized as 1 of the histopathologic patterns of HCC.© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.